Reproterol

Generic name
Reproterol
Brand name
ATC Code
R03CC14
Compare …

Reproterol

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Asthmatic status
  • Intravenous
    • 3 months up to 18 years
      • Initial dose: 1 microg./kg/minute in 10 minutes. or alternatively 1,2 microg/kg/dose as a bolus injection.
      • Maintenance dose: titrate maintenance dose dependent on effect and under control of heart rate (max. 200/min) in steps of 0,1 microg/kg/min every 10-30 min up to 0.2 - 2 microg./kg/minute, continuous infusion.
      • Duration of treatment:

        36-48 hours

      • Phase-out over 6-24 hours.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ADRENERGICS FOR SYSTEMIC USE

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Selective beta-2-adrenoreceptor agonists
R03CC02

References

  1. MEDA Pharma GmbH & Co. KG, SmPC Bronchospasmin® 1 ml Injektionslösung (82718.00.00), 09/2020
  2. MEDA Pharma GmbH & Co. KG, SmPC Bronchospasmin® 10 ml Injektionslösung (82719.00.00), 08/2020

Changes

Therapeutic Drug Monitoring


Overdose